CILP-1 levels were significantly higher in AMI patients (1650.3 ng/L) compared to the non-MACE group (976.40 ng/L), indicating its prognostic value for predicting MACE in elderly AMI patients.
Cohort (n=1,869)
No
Does elevated plasma CILP-1 predict major adverse cardiovascular events in elderly patients with acute myocardial infarction?
Elevated plasma CILP-1 levels upon admission are independently associated with myocardial ischemia, ventricular remodeling, and an increased risk of 12-month MACE in elderly patients with acute myocardial infarction.
Effect estimate: HR 1.49
Absolute Event Rate: 1650.3% vs 976.4%
p-value: P<0.05
To investigate the levels of human cartilage intermediate layer protein 1 (CILP-1) in elderly patients with acute myocardial infarction (AMI), its correlation with myocardial ischemia and ventricular remodeling, and its prognostic value for major adverse cardiovascular events (MACE). A total of 1869 elderly patients admitted to the Second Affiliated Hospital of Soochow University for chest pain within 24 h of onset were enrolled. Participants were categorized into the AMI group (n = 849) and the non-AMI group (n = 1020). The plasma CILP-1 levels were measured upon admission. In the AMI group, the wall motion score (WMS) was recorded within 24 h of pain onset, and the SYNTAX score was evaluated based on coronary angiography. Statistical analysis of MACE occurrence during 12-month follow-up was performed in the AMI patients. CILP-1 levels were significantly higher in the AMI group compared to the non-AMI group (1058.33 793.73, 1397.05 ng/L vs. 975.60 700.24, 1279.41 ng/L, P < 0.05), and notably higher in the MACE group than in the non-MACE group (1650.3 1074.61, 1718.04 ng/L vs. 976.40 738.00, 1287.78 ng/L, P < 0.05). CILP-1 expression correlated positively with WMS, SYNTAX score, myocardial injury markers, C-reactive protein (CRP), and left-ventricular end-diastolic diameter (LVDd), and negatively with left-ventricular ejection fraction (LVEF) (P < 0.05). Univariate Cox analysis indicated that CILP-1, age, cardiac troponin T (cTn-T), creatine kinase-MB (CK-MB), myoglobin, CRP, LVEF, WMS, and SYNTAX were significant predictors of MACE in AMI patients (P < 0.05). After adjusting for confounding factors, CK-MB, LVEF, WMS, and SYNTAX remained independent predictors of MACE (P < 0.05). Furthermore, incorporating CILP-1 into a baseline model (comprising LVEF, male sex, SYNTAX, WMS, CRP, and CK-MB) significantly enhanced risk estimation for MACE (AUC 0.78, 95% CI:0.75–0.80 vs. AUC 0.59, 95% CI:0.55–0.62; P < 0.05). Elderly AMI patients present significantly elevated CILP-1 levels, which positively correlate with the degree of ischemia and ventricular remodeling. CILP-1 may serve as a potential prognostic biomarker for risk stratification in elderly AMI patients.
Xiang et al. (Tue,) conducted a cohort in acute myocardial infarction (n=1,869). CILP-1 vs. non-AMI group was evaluated on major adverse cardiovascular events (MACE) (HR 1.49, p=P<0.05). CILP-1 levels were significantly higher in AMI patients (1650.3 ng/L) compared to the non-MACE group (976.40 ng/L), indicating its prognostic value for predicting MACE in elderly AMI patients.